

Please add the following new claims:

- Sub B' }
- 15. A tumor vaccine based on tumor antigens comprising a tumor antigen source and a release system with delayed release of the active substance for IFN- γ , the effective dose of IFN- γ being between 50 ng to 5 ug and the release interval being from half an hour to 8 days.
16. The tumor vaccine of claim 15, wherein the effective dose of the IFN- γ is 100 ng to 2 ug.
17. The tumor vaccine of claim 16, wherein the effective dose of IFN- γ is 100 ng to 1 ug.
- A2
- ^{10³} 18. The tumor vaccine of claim 15, wherein the release interval is from half an hour to 2 to 3 days.
- ^{10³} 19. The tumor vaccine of claim 18, wherein about 75% of the dose of IFN- γ is released within an interval of between one hour and 3 days.
-
20. The tumor vaccine of claim 15, wherein the release system with delayed release of the active substance consists of liposomes.
21. The tumor vaccine of claim 20, wherein the liposomes contain >90% of the IFN- γ enclosed therein and <10% adsorbed on the outside.
- Only C2

22. The tumor vaccine of claim 15, wherein the release system with delayed release of the active substance consists of microspheres.

23. The tumor vaccine of claim 15, wherein the release system with delayed release of the active substance consists of minipellets.

10⁷ 24. The tumor vaccine of claim 15, wherein the tumor antigen source consist of tumor cells.

10⁷ 25. The tumor vaccine of claim 24, wherein the tumor cells are allogenic tumor cells.

26. The tumor vaccine of claim 24, wherein the tumor cells are charged with peptides derived from tumor antigens.

27. The tumor vaccine of claim 15, wherein the tumor antigen source consists of antigen-presenting cells which are charged with tumor antigen peptides.

28. The tumor vaccine of claim 15, wherein the tumor antigen source consists of tumor antigens as such or peptides derived therefrom.

Remarks

Upon entry of the foregoing amendment, claims 15-28 are pending in the application, with claim 15 being an independent claim. Claims 1-14 are sought to be canceled without prejudice or disclaimer of the subject matter therein.